State Street Corp Inhibrx, Inc. Transaction History

State Street Corp

$2.25 Trillion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $25.6 Million - $30.9 Million	781,858 Added 47.8%	2,417,584 $84.5 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $274,847 - $720,290	18,955 Added 1.17%	1,635,726 $62.2 Million
Q3 2023 Nov 14, 2023	SELL	$15.75 - $26.31 $3.16 Million - $5.28 Million	-200,645 Reduced 11.04%	1,616,771 $29.7 Million
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $4.39 Million - $7.19 Million	-258,574 Reduced 12.46%	1,817,416 $47.2 Million
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $7.95 Million - $11.7 Million	-430,998 Reduced 17.19%	2,075,990 $39.2 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $9.42 Million - $15.6 Million	466,934 Added 22.89%	2,506,988 $61.8 Million
Q3 2022 Nov 15, 2022	BUY	$11.58 - $24.73 $17.5 Million - $37.3 Million	1,506,986 Added 282.7%	2,040,054 $36.6 Million
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $9.06 Million - $26.9 Million	-1,063,027 Reduced 66.6%	533,068 $6.05 Million
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $13.7 Million - $29.6 Million	686,587 Added 75.49%	1,596,095 $35.6 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $10.6 Million - $18.2 Million	396,256 Added 77.2%	909,508 $39.7 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $2.12 Million - $3.18 Million	84,025 Added 19.58%	513,252 $17.1 Million
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $3.95 Million - $7.41 Million	269,220 Added 168.26%	429,227 $11.8 Million
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $447,099 - $1.13 Million	27,480 Added 20.74%	160,007 $3.21 Million
Q4 2020 Feb 16, 2021	BUY	$15.96 - $50.0 $2.12 Million - $6.63 Million	132,527 New	132,527 $4.37 Million

Others Institutions Holding INBX

# of Institutions

Shares Held

25.3K

Call Options Held

Put Options Held

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account